National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 45254 [2013-17918]
Download as PDF
<![CDATA[
tkelley on DSK3SPTVN1PROD with NOTICES
45254
Federal Register / Vol. 78, No. 144 / Friday, July 26, 2013 / Notices
received only during the formal public
comment periods, which will be
indicated on the preliminary agenda.
The access number for the
teleconference line will be provided to
registrants by email prior to the meeting.
Persons wishing to present oral
comments are encouraged to pre-register
on the SACATM meeting registration
form (https://ntp.niehs.nih.gov/go/
32822), indicate whether they will
present comments in-person or via the
teleconference line, indicate the topic(s)
on which they plan to comment, and
send a copy of their statement to Dr.
White (whiteld@niehs.nih.gov) by
September 17, to enable review by
SACATM, NICEATM, ICCVAM, and
NIEHS/NTP staff prior to the meeting.
Written statements can supplement and
may expand the oral presentation. If
registering on-site and reading from
written text, please bring 40 copies of
the statement for distribution and to
supplement the record.
Background Information on ICCVAM,
NICEATM, and SACATM: ICCVAM is
an interagency committee composed of
representatives from 15 Federal
regulatory and research agencies that
require, use, generate, or disseminate
toxicological and safety testing
information. ICCVAM conducts
technical evaluations of new, revised,
and alternative safety testing methods
with regulatory applicability and
promotes the scientific validation and
regulatory acceptance of toxicological
and safety-testing methods that more
accurately assess the safety and hazards
of chemicals and products and that
reduce, refine (decrease or eliminate
pain and distress), or replace animal
use. The ICCVAM Authorization Act of
2000 (42 U.S.C. 285l–3) established
ICCVAM as a permanent interagency
committee of the NIEHS under
NICEATM. NICEATM administers
ICCVAM, provides scientific and
operational support for ICCVAM-related
activities, and conducts independent
validation studies to assess the
usefulness and limitations of new,
revised, and alternative test methods
and strategies. NICEATM and ICCVAM
work collaboratively to evaluate new
and improved test methods and
strategies applicable to the needs of U.S.
Federal agencies. NICEATM and
ICCVAM welcome the public
nomination of new, revised, and
alternative test methods and strategies
for validation studies and technical
evaluations. Additional information
about ICCVAM and NICEATM can be
found at https://iccvam.niehs.nih.gov.
SACATM was established in response
to the ICCVAM Authorization Act
[Section 285l–3(d)] and is composed of
VerDate Mar<15>2010
18:54 Jul 25, 2013
Jkt 229001
scientists from the public and private
sectors. SACATM advises ICCVAM,
NICEATM, and the Director of the
NIEHS and NTP regarding statutorily
mandated duties of ICCVAM and
activities of NICEATM. SACATM
provides advice on priorities and
activities related to the development,
validation, scientific review, regulatory
acceptance, implementation, and
national and international
harmonization of new, revised, and
alternative toxicological test methods.
Additional information about SACATM,
including the charter, roster, and
records of past meetings, can be found
at https://ntp.niehs.nih.gov/go/167.
Dated: July 17, 2013.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2013–17919 Filed 7–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; MSM Program
Review.
Date: October 11, 2013.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza 959, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Manana Sukhareva, Ph.D.,
Scientific Review Officer, National Institute
of Biomedical Imaging and Bioengineering,
6707 Democracy Boulevard Suite 959,
Bethesda, MD 20892, 301–451–3397,
sukharem@mail.nih.gov.
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Dated: July 19, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–17918 Filed 7–25–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Proposed Collection;
Comment Request
In compliance with Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 concerning
opportunity for public comment on
proposed collections of information, the
Substance Abuse and Mental Health
Services Administration (SAMHSA)
will publish periodic summaries of
proposed projects. To request more
information on the proposed projects or
to obtain a copy of the information
collection plans, call the SAMHSA
Reports Clearance Officer on (240) 276–
1243.
Comments are invited on: (a) Whether
the proposed collections of information
are necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Proposed Project: SAMHSA Tobacco
Prevention, Cessation, and Behavioral
Health Message Testing—NEW
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is conducting message
testing to inform the development and
implementation of a tobacco use
prevention and cessation campaign
aimed at youth with substance use and/
or mental health conditions.
The purpose of the project is to
inform messaging efforts, through focus
groups with youth and in-depth
interviews with health care providers, to
improve tobacco use prevention and
cessation efforts in populations with
mental health and substance use
concerns, particularly youth and
vulnerable populations. The focus
groups and interviews are an integral
E:\FR\FM\26JYN1.SGM
26JYN1
]]>Agencies
[Federal Register Volume 78, Number 144 (Friday, July 26, 2013)]
[Notices]
[Page 45254]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-17918]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel; MSM Program Review.
Date: October 11, 2013.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza 959,
6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Manana Sukhareva, Ph.D., Scientific Review
Officer, National Institute of Biomedical Imaging and
Bioengineering, 6707 Democracy Boulevard Suite 959, Bethesda, MD
20892, 301-451-3397, sukharem@mail.nih.gov.
Dated: July 19, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-17918 Filed 7-25-13; 8:45 am]
BILLING CODE 4140-01-P
